Key features of GBM include overactive receptor tyrosine kinase signaling, loss of p53, and stem-like properties that underpin treatment resistance (Venkataramani et al., 2019; Virtuoso et al., 2021; Wang et al., 2021). This evidence concerns the gene TP53 and glioblastoma.